Immunohistochemical Expression of Endothelin-1 and Endothelin-A and Endothelin-B Receptors in High-Grade Prostatic Intraepithelial Neoplasia and Prostate Cancer

Rodolfo Montironi, Roberta Mazzucchelli, Francesca Barbisan, Daniela Stramazzotti, Alfredo Santinelli, Antonio Lòpez Beltran, Liang Cheng, Francesco Montorsi, Marina Scarpelli

Research output: Contribution to journalArticle

24 Scopus citations

Abstract

Objectives: To analyze the expression of endothelin-1 (ET-1), endothelin-A receptor (ET-A-R), and endothelin-B receptor (ET-B-R) in incidental prostate cancer in cystoprostatectomies (CyPs), clinically detected hormonally untreated and hormonally treated prostate cancer in radical prostatectomies (RPs), and hormone-independent prostate cancer in transurethral resections of the prostate (TURPs). High-grade prostatic intraepithelial neoplasia (HGPIN) was also investigated. Methods: Nineteen CyPs and 44 RPs (25 untreated, 19 treated) with pT2a Gleason score 6 cancer and HGPIN were examined. The study included 9 TURPs with hormone-independent cancer and 8 normal cases from CyPs without prostate cancer and HGPIN. ET-1, ET-A-R, ET-B-R, and the proliferation marker Ki67 were investigated immunohistochemically. Results: The mean proportion of prostate cancer cells with strong ET-1, ET-A-R, and ET-B-R expression in CyPs was lower (18.5%, 28.0%, and 14.7%, respectively) than in the untreated group (40.7%, 39.7%, and 25.1%) and higher than in treated group (5.0%, 13.9%, and 11.3%). The highest values were in the hormone-independent cancer group (53.9%, 48.9%, 33.3%). The trend in the proportion of HGPIN cells overexpressing ET-1, ET-A-R, and ET-B-R was similar to that in the cancer groups. The values in HGPIN lesions were always slightly greater than those in the cancers. Ki67 expression in HGPIN and prostate cancer in CyPs was lower than in RPs and TURPs. Conclusions: Our study showed for the first time that ET-1, ET-A-R, and ET-B-R expression is not limited to the late prostate cancer phases. It is also seen in HGPIN as well as in prostate cancers considered to be clinically insignificant, such as those seen in CyP specimens. Although the series of cases in each group was small, our data may have clinical significance.

Original languageEnglish (US)
Pages (from-to)1682-1690
Number of pages9
JournalEuropean urology
Volume52
Issue number6
DOIs
StatePublished - Dec 1 2007

Keywords

  • Cystoprostatectomy
  • Endothelin-1
  • Endothelin-A receptor
  • Endothelin-B receptor
  • High-grade prostatic intraepithelial neoplasia
  • Insignificant cancer
  • Prostate cancer
  • Significant cancer

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Immunohistochemical Expression of Endothelin-1 and Endothelin-A and Endothelin-B Receptors in High-Grade Prostatic Intraepithelial Neoplasia and Prostate Cancer'. Together they form a unique fingerprint.

  • Cite this

    Montironi, R., Mazzucchelli, R., Barbisan, F., Stramazzotti, D., Santinelli, A., Lòpez Beltran, A., Cheng, L., Montorsi, F., & Scarpelli, M. (2007). Immunohistochemical Expression of Endothelin-1 and Endothelin-A and Endothelin-B Receptors in High-Grade Prostatic Intraepithelial Neoplasia and Prostate Cancer. European urology, 52(6), 1682-1690. https://doi.org/10.1016/j.eururo.2007.02.024